Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Holdings Decreased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,454 shares of the company’s stock after selling 694 shares during the period. Mutual of America Capital Management LLC’s holdings in Medpace were worth $4,431,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. RiverPark Advisors LLC bought a new stake in shares of Medpace in the 4th quarter worth about $26,000. Contravisory Investment Management Inc. bought a new stake in shares of Medpace in the 4th quarter worth about $26,000. Altshuler Shaham Ltd bought a new stake in shares of Medpace in the 4th quarter worth about $27,000. FinTrust Capital Advisors LLC bought a new stake in shares of Medpace in the 3rd quarter worth about $30,000. Finally, Rockefeller Capital Management L.P. increased its position in shares of Medpace by 361.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock worth $30,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Company insiders own 20.30% of the company’s stock.

Medpace Stock Down 2.0 %

Shares of NASDAQ:MEDP opened at $387.14 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $185.43 and a fifty-two week high of $419.42. The firm has a 50-day simple moving average of $390.63 and a 200 day simple moving average of $317.22. The company has a market cap of $11.99 billion, a PE ratio of 43.60, a P/E/G ratio of 2.09 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.24. The firm had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. Medpace’s revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.12 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 10.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 14th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $382.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.